Welcome to our dedicated page for Moleculin Biotec SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moleculin Biotech, Inc. (Nasdaq: MBRX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding Moleculin’s progress as a Phase 3 clinical stage pharmaceutical company focused on hard-to-treat tumors and certain viral infections.
Through Moleculin’s Form 8-K current reports, investors can review material events such as clinical and scientific milestones, corporate presentations, patent developments, financing transactions and listing-related communications. Recent 8-K filings have furnished press releases on positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors, updates on enrollment and unblinding plans for the pivotal MIRACLE Phase 2B/3 AML trial of Annamycin plus cytarabine (AnnAraC), and independent assessments of Annamycin’s cardiotoxicity profile. Other 8-Ks describe grant-funded and investigator-initiated research agreements for Annamycin in pancreatic cancer and glioblastoma multiforme, as well as patent grants for preliposomal Annamycin lyophilizates.
Moleculin’s filings also document capital markets and listing matters, including notices from Nasdaq regarding bid price and stockholders’ equity requirements, the company’s responses and appeal plans, and the implementation of a 1-for-25 reverse stock split with continued trading under the MBRX symbol. Additional filings cover warrant exercises, special stockholder meeting results and approvals related to equity issuances.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, such as clinical trial status, regulatory designations, patent protections and financing terms. Users can quickly scan 8-Ks and related reports to understand how Moleculin is advancing Annamycin, WP1066 and WP1122, how it is managing its Nasdaq listing, and how corporate actions may affect shareholders. This page also helps surface insider and governance-related information when reported through the company’s SEC submissions.
Moleculin Biotech (MBRX) has announced a significant public offering totaling $5.9 million in gross proceeds, with potential for an additional $17.8 million if all warrants are exercised. The offering, which closed on June 23, 2025, includes:
- 9,972,026 shares of common stock
- 6,107,974 pre-funded warrants at $0.001 exercise price
- 48,240,000 Series E warrants at $0.37 initial exercise price
Notable aspects include insider participation, with CEO Walter Klemp and CFO Jonathan Foster purchasing 1,027,026 shares and 3,081,078 warrants. Roth Capital Partners served as placement agent, receiving a 7% fee. The proceeds will fund clinical development of Annamycin and two other drug portfolios, preclinical studies, and working capital.
The offering includes significant stockholder approval requirements and anti-dilution provisions, with warrant exercise prices subject to potential downward adjustments (floor price $0.12). The company has agreed to a 60-day restriction on new share issuances following stockholder approvals.
Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech (MBRX), reported multiple securities transactions on June 20-23, 2025:
- Acquired 2,711 shares from RSUs and had 661 shares withheld for taxes on June 20
- Acquired 4,328 shares from RSUs and had 1,054 shares withheld for taxes on June 22
- Purchased 270,270 common shares at $0.37 per share in a public offering on June 23
- Acquired Series E warrants to purchase 810,810 shares at $0.37/share, exercisable upon stockholder approval with 5-year expiration
Following these transactions, Foster directly owns 287,587 common shares and 1,038,320 derivative securities. The RSUs were granted in 2022 (10,846 units) and 2023 (17,313 units), vesting in four annual installments. This significant insider purchase demonstrates management's confidence in the company's prospects.
Walter V. Klemp, CEO, President and Director of Moleculin Biotech (MBRX), reported multiple insider transactions on June 20-23, 2025:
- Acquired 3,750 shares from RSU vesting on June 20, with 914 shares withheld for taxes
- Acquired 8,990 shares from RSU vesting on June 22, with 2,190 shares withheld for taxes
- Purchased 675,675 common shares at $0.37 per share in a public offering on June 23
- Acquired Series E warrants to purchase 2,027,025 additional shares at $0.37/share
Following these transactions, Klemp directly owns 743,607 common shares and 2,409,481 derivative securities. The Series E warrants will be exercisable upon stockholder approval and expire 5 years after approval. These transactions demonstrate significant insider investment in the company, particularly through participation in the public offering.
Donald H. Picker, Chief Science Officer of Moleculin Biotech (MBRX), reported multiple transactions involving restricted stock units (RSUs) and common stock:
- On June 20, 2025, converted 1,078 RSUs to common stock and had 263 shares withheld for tax purposes at $0.267 per share, resulting in 8,816 directly owned shares
- On June 22, 2025, converted 1,766 RSUs to common stock and had 430 shares withheld for tax purposes at $0.267 per share, resulting in 10,152 directly owned shares
These transactions stem from two RSU grants: 4,312 units granted on June 20, 2022, and 7,063 units granted on June 22, 2023, both vesting in four equal annual installments. Following these transactions, Picker maintains direct ownership of 104,258 RSUs.
Moleculin Biotech (MBRX) has announced a public offering of securities including 9,972,026 shares of common stock and Series E warrants to purchase up to 29,916,078 shares, along with 6,107,974 pre-funded warrants and accompanying Series E warrants.
Key offering details:
- Combined purchase price: $0.37 per share and accompanying warrant
- Series E warrants exercise price: $0.37 per share, expires 5 years from stockholder approval
- Pre-funded warrants exercise price: $0.001 per share
- Total expected proceeds: $5.95 million before expenses
- Placement agent: Roth Capital Partners, receiving 7% fee
The company is conducting a Phase 3 trial of Annamycin for relapsed/refractory acute myeloid leukemia, with interim data expected by end of 2025. Management, including CEO Walter Klemp and CFO Jonathan Foster, will participate in the offering by purchasing 1,027,026 shares with warrants. The offering closes around June 23, 2025.
The Securities and Exchange Commission has declared Moleculin Biotech's Form S-1 registration statement effective as of June 20, 2025, at 9:00 A.M. The Form S-1 (File Number: 333-287727) represents a significant regulatory milestone for the company.
A Form S-1 effectiveness notice typically indicates that the company has received regulatory approval to proceed with:
- Initial public offering (IPO)
- Follow-on public offering
- Registration of securities for sale to the public
This development enables Moleculin Biotech (MBRX) to move forward with its planned securities offering, having satisfied SEC registration requirements. Investors should refer to the full S-1 filing for detailed information about the offering terms, use of proceeds, and associated risks.
Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech (MBRX), reported insider transactions on June 16, 2025:
- Acquired 833 shares of common stock through the conversion of Restricted Stock Units (RSUs)
- Disposed of 203 shares at $0.6852 per share for tax withholding
- Following these transactions, Foster directly owns 11,993 shares of common stock
- Maintains 230,684 RSUs from a June 16, 2021 grant of 3,334 units that vest in four equal annual installments
These transactions represent routine vesting of executive compensation RSUs rather than open market purchases or sales. The tax-related share withholding is a standard practice for handling tax obligations from equity compensation vesting.
FAQ
What is the current stock price of Moleculin Biotec (MBRX)?
What is the market cap of Moleculin Biotec (MBRX)?
